표적 단백질 분해(TPD) 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 투여 경로별, 단계별(-2035년)

Targeted Protein Degradation Market is anticipated to expand from $0.6 billion in 2024 to $9.5 billion by 2034, growing at a CAGR of approximately 31.8%. The Targeted Protein Degradation Market encompasses innovative therapies designed to selectively degrade disease-causing proteins, offering a novel approach beyond traditional inhibition. This market leverages proteolysis-targeting chimeras (PROTACs) and molecular glues, facilitating precise therapeutic interventions. With rising interest in oncology and neurodegenerative disorders, the market is poised for growth, driven by advancements in drug discovery technologies and strategic collaborations among pharmaceutical giants.

The Targeted Protein Degradation Market is poised for significant growth, driven by advancements in drug discovery and personalized medicine. The small molecule degraders segment leads in performance, primarily due to their ability to target previously 'undruggable' proteins. Heterobifunctional degraders, a sub-segment within small molecule degraders, are gaining traction, offering enhanced specificity and efficacy. The PROTACs (Proteolysis Targeting Chimeras) sub-segment is the second highest performing, reflecting its promising therapeutic potential and versatility across various disease areas. Meanwhile, the therapeutic area segment is dominated by oncology applications, given the urgent need for novel cancer treatments. Neurological disorders follow closely, driven by increasing research into neurodegenerative diseases. The burgeoning interest in targeted therapies is fostering collaboration between pharmaceutical companies and research institutions, accelerating innovation. The integration of artificial intelligence in drug discovery processes further supports market expansion, optimizing target identification and enhancing drug development pipelines.

Market Snapshot:

The Targeted Protein Degradation Market is experiencing a dynamic shift with significant market share held by key industry leaders. Pricing strategies remain competitive, influenced by the introduction of novel therapeutics and advancements in drug discovery. Recent product launches have invigorated the market, as companies strive to address unmet medical needs and enhance therapeutic efficacy. The focus on personalized medicine and targeted therapies continues to drive innovation, setting the stage for sustained growth in this sector. Competition within the Targeted Protein Degradation Market is intense, with major players vying for dominance through strategic partnerships and mergers. Regulatory influences, particularly in the United States and Europe, play a crucial role in shaping market dynamics. These regulations ensure safety and efficacy, impacting the pace of product approvals and market entry. Benchmarking against competitors reveals an emphasis on research and development, aiming to leverage cutting-edge technologies. The market's trajectory is promising, with advancements in biotechnology and increased investment in R&D fueling further expansion.

Geographical Overview:

The Targeted Protein Degradation (TPD) market is witnessing robust growth across diverse regions, each demonstrating unique potential. North America leads the charge, propelled by cutting-edge research and substantial investments in biotechnology. The region's focus on innovative drug discovery and development further bolsters this market, positioning it as a growth leader. In Europe, the TPD market is gaining momentum, driven by strong governmental support and a well-established pharmaceutical industry. The region's emphasis on precision medicine and advanced therapeutic solutions enhances its market prospects. Meanwhile, Asia Pacific is emerging as a significant growth pocket, fueled by rapid technological advancements and increasing investments in healthcare R&D. Countries like China and Japan are at the forefront, spearheading initiatives in targeted therapies. Latin America and the Middle East & Africa are nascent markets with burgeoning potential. These regions are increasingly recognizing the importance of TPD in addressing unmet medical needs and advancing therapeutic innovation.

Key Trends and Drivers:

The Targeted Protein Degradation Market is experiencing rapid growth, driven by several key trends and drivers. Increasing investment in biotechnology and pharmaceutical research is a primary driver, as companies seek innovative therapies for complex diseases. This trend is supported by advancements in proteomics and bioinformatics, which enhance the understanding of protein interactions and degradation pathways. A growing focus on precision medicine is also fueling market expansion, as targeted protein degradation offers more specific treatment options with potentially fewer side effects. Collaborations between academic institutions and industry players are accelerating the development of novel degradation technologies. The rise of small molecule degraders, such as PROTACs and molecular glues, is a significant trend, offering new mechanisms to target previously 'undruggable' proteins. Furthermore, regulatory support and expedited approval processes for breakthrough therapies are encouraging innovation in this market. Companies investing in robust pipelines and strategic partnerships are well-positioned to capitalize on these emerging opportunities, driving future growth and market leadership.

Restraints and Challenges:

The targeted protein degradation market encounters several notable restraints and challenges. A primary challenge is the complexity of drug development processes, which can result in extended timelines and increased costs. This complexity often deters investment and slows the pace of innovation. Regulatory hurdles also pose significant obstacles, as the evolving landscape requires compliance with stringent guidelines that can delay market entry. Additionally, there is a lack of standardized protocols for evaluating the efficacy and safety of targeted protein degraders. This absence complicates clinical trial designs and hinders the establishment of robust benchmarks for success. Intellectual property issues further exacerbate market challenges, with patent conflicts potentially stifling competition and innovation. Lastly, the market faces a scarcity of skilled professionals with expertise in this niche domain. This talent gap limits the capacity for research and development, impeding overall market growth and advancement. These factors collectively restrain the potential of the targeted protein degradation market.

Key Players:

Arvinas, Nurix Therapeutics, Kymera Therapeutics, C4 Therapeutics, Foghorn Therapeutics, Vividion Therapeutics, Monte Rosa Therapeutics, Cullgen, Dialectic Therapeutics, Mission Therapeutics, Progenra, Cedilla Therapeutics, Kymera Therapeutics, Bicycle Therapeutics, Forma Therapeutics

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Small Molecules
  • 4.1.2 Biologics
  • 4.1.3 PROTACs
  • 4.1.4 Molecular Glues
  • 4.1.5 Degronimids
  • 4.1.6 E3 Ligase Modulators
  • 4.1.7 Chaperone-Mediated Degraders
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Agents
  • 4.2.2 Research Tools
  • 4.2.3 Diagnostic Agents
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Custom Synthesis
  • 4.3.2 Drug Discovery Services
  • 4.3.3 Analytical Services
  • 4.3.4 Consulting Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Ubiquitin-Proteasome System
  • 4.4.2 Autophagy-Lysosome Pathway
  • 4.4.3 Endoplasmic Reticulum-Associated Protein Degradation
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Neurology
  • 4.5.3 Infectious Diseases
  • 4.5.4 Cardiovascular Diseases
  • 4.5.5 Immunology
  • 4.5.6 Metabolic Disorders
  • 4.5.7 Ophthalmology
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Academic and Research Institutions
  • 4.6.4 Contract Research Organizations
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Discovery
  • 4.7.2 Preclinical Development
  • 4.7.3 Clinical Trials
  • 4.7.4 Regulatory Approval
  • 4.7.5 Commercialization
  • 4.7.6 Post-Market Surveillance
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 Oral
  • 4.8.2 Intravenous
  • 4.8.3 Subcutaneous
  • 4.8.4 Topical
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Preclinical
  • 4.9.2 Phase I
  • 4.9.3 Phase II
  • 4.9.4 Phase III
  • 4.9.5 Approved

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Mode
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Mode
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Mode
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Mode
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Mode
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Mode
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Mode
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Mode
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Mode
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Mode
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Mode
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Mode
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Mode
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Mode
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Mode
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Mode
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Mode
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Mode
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Mode
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Mode
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Mode
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Mode
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Mode
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Mode
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Arvinas
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Nurix Therapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Kymera Therapeutics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 C4 Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Foghorn Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Vividion Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Monte Rosa Therapeutics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Cullgen
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Dialectic Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Mission Therapeutics
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Progenra
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Cedilla Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Kymera Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Bicycle Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Forma Therapeutics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us